Novartis AG (NVS)

91.09
1.30 1.40
NYSE : Health Technology
Prev Close 92.37
Open 91.57
Day Low/High 90.94 / 91.67
52 Wk Low/High 72.30 / 96.31
Volume 1.61M
Avg Volume 2.53M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 236.17B
EPS 5.50
P/E Ratio 17.17
Div & Yield 1.84 (1.99%)

Latest News

Novartis Shows Growing Strength In Lung Cancer Innovation With New Capmatinib Investigational Data And Novel Canakinumab Clinical Trials

Novartis Shows Growing Strength In Lung Cancer Innovation With New Capmatinib Investigational Data And Novel Canakinumab Clinical Trials

- Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon-14 skipping mutation

AveXis Receives FDA Approval For Zolgensma®, The First And Only Gene Therapy For Pediatric Patients With Spinal Muscular Atrophy (SMA)

AveXis Receives FDA Approval For Zolgensma®, The First And Only Gene Therapy For Pediatric Patients With Spinal Muscular Atrophy (SMA)

- SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2[1,2]

Stocks We Are Looking at During Thursday's Early Declines

Our preference is to make smaller, incremental buys as the market comes in.

Jim Cramer: Trump Cares More About Beating the Chinese Than Earnings Reports

Jim Cramer: Trump Cares More About Beating the Chinese Than Earnings Reports

Jim Cramer weighs in on why President Trump cares more about 'beating the Chinese' than the earnings reports that we receive from companies.

Novartis Is a Difficult Stock to Trade or Own - Suggested Risk Point

Novartis Is a Difficult Stock to Trade or Own - Suggested Risk Point

Let's review the charts and indicators this morning.

In the Crosshairs of the Trade War: Cramer's 'Mad Money' Recap (Tuesday 5/21/19)

In the Crosshairs of the Trade War: Cramer's 'Mad Money' Recap (Tuesday 5/21/19)

Jim Cramer reviews stocks poised to profit, and those at risk -- until we get some sign of a truce in the trade war.

McDonald's, Kinder Morgan, Intel: 'Mad Money' Lightning Round

McDonald's, Kinder Morgan, Intel: 'Mad Money' Lightning Round

Jim Cramer is taking a closer look at McDonald's, Kinder Morgan, Intel, Nektar Therapeutics, L Brands, Scientific Games, and more.

Jim Cramer: The Forbidden City of Stock Sectors

Jim Cramer: The Forbidden City of Stock Sectors

Now, we know that if we got any sort of truce in the trade war, with the exception of the financials, these hated sectors would be loved.

Teva Falls as Drugmakers Alleged to Have Artificially Inflated Prices

Teva Falls as Drugmakers Alleged to Have Artificially Inflated Prices

Attorneys general from 44 states allege the nation's largest generic drugmakers conspired to artificially inflate and manipulate prices for more than 100 different generic drugs.

Stock Selloff, Trade War, Teva, Take-Two and Oil Prices - 5 Things You Must Know

Stock Selloff, Trade War, Teva, Take-Two and Oil Prices - 5 Things You Must Know

U.S. stock futures fall sharply after China vows to stand its ground in the escalating trade war with the United States; oil prices surge after Saudi Arabia alleges two of its tankers were victims of a 'sabotage attack,' Teva and other drugmakers are alleged to have conspired to artificially inflate and manipulate prices for generic drugs.

Novartis to Buy Takeda's Eye Drug in $5.3 Billion Deal

Novartis to Buy Takeda's Eye Drug in $5.3 Billion Deal

Novartis gets a potentially blockbuster eye drug and Takeda gets to unload some debt and employees it took on when it purchased Shire.

Why CBD's Invasion Into Pantries and Medicine Cabinets Is Inevitable

Why CBD's Invasion Into Pantries and Medicine Cabinets Is Inevitable

Cannabis' non-psychoactive derivative could disrupt the CPG (Consumer Product Group) space very soon. Watch the video for the more on the opportunities and challenges.

Alcon Begins Trading After Spinoff From Novartis

Alcon Begins Trading After Spinoff From Novartis

Alcon begins trading after its spinoff from parent company Novartis.

Markets Begin Monday Lower; Amgen and Lam Research Updates

A look at Amgen's dispute with Novartis as well as Lam Research stock.

Novartis Multiple Sclerosis Drug With Price Tag of $88,000 Gets FDA Nod

Novartis Multiple Sclerosis Drug With Price Tag of $88,000 Gets FDA Nod

Mayzent tablets to treat relapsing multiple sclerosis have been approved by the FDA. But the treatment comes with a hefty price tag.

The Fed's March Meeting: 3 Things Stock Investors Should Look Out For

The Fed's March Meeting: 3 Things Stock Investors Should Look Out For

Plus, why investors should care about the yield curve, and a closer look at Tilray's quarter.

Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space

Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space

Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.

Tilray Stock Lights Up as Partnerships Obscure Profitability Problem

Tilray Stock Lights Up as Partnerships Obscure Profitability Problem

The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.

Jim Cramer: How to Win Now, With or Without China

Jim Cramer: How to Win Now, With or Without China

If we can advance without China then who the heck knows where we can go with it.

Spark Therapeutics Rockets as Roche Pays $4.3 Billion for Gene Therapy Experts

Spark Therapeutics Rockets as Roche Pays $4.3 Billion for Gene Therapy Experts

Spark Therapeutics shares more than double Monday after the gene therapy specialist agreed to a $4.3 billion takeover by Switzerland-based Roche Holding, the world's biggest maker of cancer treatments.

Gilead Shares Fall After Hours as Company Misses on Quarterly Earnings

Gilead Shares Fall After Hours as Company Misses on Quarterly Earnings

Medicine is a slow business and I view Gilead Sciences as a hold for now.

Excuse Me, Would You Like Some Cannabis With Your Coffee?

Excuse Me, Would You Like Some Cannabis With Your Coffee?

CBD could make coffee an around the clock craze.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Big pharma is shaping up to be a consolidating category in 2019.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Tumultuous, but Positive: Cramer's 'Mad Money' Recap (Friday 1/11/19)

Tumultuous, but Positive: Cramer's 'Mad Money' Recap (Friday 1/11/19)

This will be the craziest reporting season we've seen in ages, says Jim Cramer. He's got your game plan for next week.

Chart of the Day, Part 2: A Closer Look at Constellation's Big Cannabis Bet

Chart of the Day, Part 2: A Closer Look at Constellation's Big Cannabis Bet

Canopy Growth's smoking engine won't necessarily ensure smooth sailing for Constellation.

Novartis Stock Is Poised to Rise Another 15% From Here

Novartis Stock Is Poised to Rise Another 15% From Here

The stock's performance has been impressive in the past three months.

Hunt for Winning Stocks: Cramer's 'Mad Money' Recap (Monday 1/7/19)

Hunt for Winning Stocks: Cramer's 'Mad Money' Recap (Monday 1/7/19)

Jim Cramer says companies that innovate become market-leading stocks, and can create tremendous wealth.

TheStreet Quant Rating: A- (Buy)